Correction - New Report Version: Klaria Interim Report Q2 2026

Summary of interim report

Second quarter of 2026

The group in total

- Net sales 0.0 MSEK (0.0 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 4.4 MSEK (7.1 MSEK)

- Profit after tax amounted to -12.9 MSEK (-20.1 MSEK)

- Earnings per share for the quarter amounted to -0.05 SEK (-0.17 SEK)

- Cash flow from operating activities amounted to -14.8 MSEK (-2.3 MSEK)

- Liquid assets on the balance sheet date amounted to 8.5 MSEK (2.0 MSEK)

- Group equity as of June 30 amounted to -33.6 MSEK (-18.4 MSEK)

- Equity in the parent company as of June 30 amounted to 79.0 MSEK (64,9 MSEK)

The period January-June 2026

The group in total

- Net sales 0.1 MSEK (9.0 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 9.3 MSEK (10.5 MSEK)

- Profit after tax amounted to -21.5 MSEK (-21.7 MSEK)

- Earnings per share for the period amounted to -0.09 SEK (-0.15 SEK)

- Cash flow from operating activities amounted to -14.9 MSEK (-1.7 MSEK)

This disclosure contains information that Klaria Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 01-09-2026 08:34 CET.